Primary Aldosteronism In Hypertensive Patients in China

Qifu Li3,500 enrolled

Overview

To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with newly diagnosed hypertension.

This is a nationwide sampling study. To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with hypertension, we will conduct a case detection of PA in Chinese hypertensive patients from 10 centers of China (including Beijing, Chongqing, Shanghai, Guangzhou, et al.); furthermore, a case confirmation of PA (captopril challenge test and saline infusion test) will be performed if the result of case detection is positive. This study will be completed in two years.

Study Type

OBSERVATIONAL

Enrollment

3,500

Conditions

Hyperaldosteronism; Primary Hypertension Secondary

Interventions

Aldosterone/renin ratio (ARR) testingDIAGNOSTIC_TEST

Plasma aldosterone concentration tests, Direct renin concentration tests

Confirmatory testsDIAGNOSTIC_TEST

Captopril challenge test, Saline infusion test

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed hypertension(with a course less than six months); 2. Drug negative, or voluntary to discontinue/change the anti-hypertensive medications; 3. Aged between 18-80 year, gender is not limited; 4. Voluntary to sign on the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis.

Locations (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Outcomes

Primary Outcomes

Number of subjects with newly diagnosed hypertension

To calculate the prevalence of PA in Chinese patients with hypertension

Time frame: 2 years

Number of subjects with confirmed primary aldosteronism (PA)

To calculate the prevalence of PA in Chinese patients with hypertension

Time frame: 2 years

Prevalence of PA

Prevalence of PA= Number of PA / Number of subjects with hypertension

Time frame: 2 years